207 related articles for article (PubMed ID: 17852772)
21. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.
Desjardins F; Sekkali B; Verreth W; Pelat M; De Keyzer D; Mertens A; Smith G; Herregods MC; Holvoet P; Balligand JL
Eur Heart J; 2008 Jan; 29(1):128-37. PubMed ID: 18063594
[TBL] [Abstract][Full Text] [Related]
22. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
Fox KM; Gandhi SK; Ohsfeldt RL; Davidson MH
Am J Manag Care; 2007 Dec; 13 Suppl 10():S270-5. PubMed ID: 18095777
[TBL] [Abstract][Full Text] [Related]
23. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
[TBL] [Abstract][Full Text] [Related]
24. Platelet activation in patients with Familial Mediterranean Fever.
Coban E; Adanir H
Platelets; 2008 Sep; 19(6):405-8. PubMed ID: 18925507
[TBL] [Abstract][Full Text] [Related]
25. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate.
Vidt DG; Harris S; McTaggart F; Ditmarsch M; Sager PT; Sorof JM
Am J Cardiol; 2006 Jun; 97(11):1602-6. PubMed ID: 16728222
[TBL] [Abstract][Full Text] [Related]
26. Antioxidant and antiplatelet effects of rosuvastatin in a hamster model of prediabetes.
Miersch S; Sliskovic I; Raturi A; Mutus B
Free Radic Biol Med; 2007 Jan; 42(2):270-9. PubMed ID: 17189832
[TBL] [Abstract][Full Text] [Related]
27. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin.
Willich SN; Englert H; Sonntag F; Völler H; Meyer-Sabellek W; Wegscheider K; Windler E; Katus H; Müller-Nordhorn J
Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):180-7. PubMed ID: 19174696
[TBL] [Abstract][Full Text] [Related]
28. Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia.
Ott C; Ritt M; Titze SI; Schäufele T; Schmieder RE
J Nephrol; 2009; 22(5):675-81. PubMed ID: 19810001
[TBL] [Abstract][Full Text] [Related]
29. Rosuvastatin reduces platelet recruitment by inhibiting NADPH oxidase activation.
Pignatelli P; Carnevale R; Di Santo S; Bartimoccia S; Nocella C; Vicario T; Loffredo L; Angelico F; Violi F
Biochem Pharmacol; 2012 Dec; 84(12):1635-42. PubMed ID: 23022230
[TBL] [Abstract][Full Text] [Related]
30. Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease.
Kapur NK
Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):161-75. PubMed ID: 17338662
[TBL] [Abstract][Full Text] [Related]
31. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus.
Schäfer A; Fraccarollo D; Vogt C; Flierl U; Hemberger M; Tas P; Ertl G; Bauersachs J
Biochem Pharmacol; 2007 May; 73(9):1367-75. PubMed ID: 17270148
[TBL] [Abstract][Full Text] [Related]
32. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
[TBL] [Abstract][Full Text] [Related]
33. Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion.
Xia W; Yin Z; Li J; Song Y; Qu X
Pacing Clin Electrophysiol; 2009 Dec; 32(12):1562-6. PubMed ID: 19793367
[TBL] [Abstract][Full Text] [Related]
34. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
Link A; Ayadhi T; Böhm M; Nickenig G
Eur Heart J; 2006 Dec; 27(24):2945-55. PubMed ID: 17012299
[TBL] [Abstract][Full Text] [Related]
35. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial.
Underhill HR; Yuan C; Zhao XQ; Kraiss LW; Parker DL; Saam T; Chu B; Takaya N; Liu F; Polissar NL; Neradilek B; Raichlen JS; Cain VA; Waterton JC; Hamar W; Hatsukami TS
Am Heart J; 2008 Mar; 155(3):584.e1-8. PubMed ID: 18294500
[TBL] [Abstract][Full Text] [Related]
36. Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloproteinase-2 activity in normocholesterolemic and hypercholesterolemic rabbits.
D'Annunzio V; Donato M; Erni L; Miksztowicz V; Buchholz B; Carrión CL; Schreier L; Wikinski R; Gelpi RJ; Berg G; Basso N
J Cardiovasc Pharmacol; 2009 Feb; 53(2):137-44. PubMed ID: 19188835
[TBL] [Abstract][Full Text] [Related]
37. Dose-dependent effect of rosuvastatin treatment on urinary protein excretion.
Kostapanos MS; Milionis HJ; Saougos VG; Lagos KG; Kostara C; Bairaktari ET; Elisaf MS
J Cardiovasc Pharmacol Ther; 2007 Dec; 12(4):292-7. PubMed ID: 18172223
[TBL] [Abstract][Full Text] [Related]
38. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients.
Sorof J; Berne C; Siewert-Delle A; Jørgensen L; Sager P;
Diabetes Res Clin Pract; 2006 Apr; 72(1):81-7. PubMed ID: 16246447
[TBL] [Abstract][Full Text] [Related]
39. The mean platelet volume in patients with obesity.
Coban E; Ozdogan M; Yazicioglu G; Akcit F
Int J Clin Pract; 2005 Aug; 59(8):981-2. PubMed ID: 16033624
[TBL] [Abstract][Full Text] [Related]
40. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Chen J; Li D; Schaefer R; Mehta JL
Atherosclerosis; 2006 Feb; 184(2):295-301. PubMed ID: 16005008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
